Huntington disease

Disease ID:442
Name:Huntington disease
Associated with:2 targets
0 immuno targets
0 immuno ligands
Huntington's disease
Database Links
Disease Ontology: DOID:12858
OMIM: 143100


C5a1 receptor
Comments:  In a rat model of 3-nitropropionic acid-induced Huntington's disease, C5aR inhibition via oral administration of either PMX53 or PMX205 reduced the behavioural phenotype and striatal lesions histologically. A decrease in striatal astrocytosis was also demonstrated, however whether this was a cause or effect of the reduction in striatal lesions was not investigated.
References:  2
References:  1


No ligand related data available for Huntington disease


Show »

1. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV et al.. (2014) Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci.17 (5): 694-703. [PMID:24686787]

2. Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, de Vos K, Pollitt S, Williams HM, Shiels IA, Monk PN et al.. (2006) Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J.20 (9): 1407-17. [PMID:16816116]